AOD-9604

Modified HGH fragment (177-191 with tyrosine extension) - designed to isolate HGH's lipolytic effects without IGF-1 elevation or insulin resistance. Clinical obesity trials failed against placebo; remains a niche for fasted-state fat loss and cartilage repair.

Research chemicalWADA S0 prohibitedInjectableLipolytic

Key facts

Common routesSC

Half-lifeShort (unknown in humans)

Typical range300–500 mcg/day

Summary

AOD-9604 is a modified synthetic fragment of the C-terminal region of human growth hormone (residues 177–191) with an added N-terminal tyrosine. Designed by Metabolic Pharmaceuticals in the 1990s with the explicit intent of isolating HGH's lipolytic properties - without the anabolic, insulin-desensitising, or IGF-1-mediated effects of the full hormone.

The original obesity indication failed in Phase 2b trials (Stier 2013) - no significant weight loss vs placebo. Development was abandoned. What remains: a well-safety-characterised peptide with real animal lipolysis signal, anecdotal body-composition use in fasted-state context, and an emerging cartilage-repair narrative from animal studies.

Mechanism notes

Beta-3 adrenergic stimulation

Increases lipolysis in adipocytes and inhibits lipogenesis. The mechanism partly runs through beta-3 adrenergic receptors, but receptor-independent effects have been observed in knockout models - the full picture isn't resolved.

No IGF-1 signal

Unlike full HGH or GH secretagogues, AOD-9604 doesn't produce an IGF-1 rise. That's the positioning rationale as "lipolytic HGH without the anabolic risks" - no IGF-1 cancer-promotion frame, no insulin-sensitivity drift, no acromegaly-like effects.

Chondrocyte regeneration

In vitro and rabbit studies (Kwon 2015) suggest AOD-9604 enhances differentiation of muscle / cartilage cells and promotes connective-tissue repair, particularly synergistic with hyaluronic acid. Human data in this application is extrapolated.

Dosing patterns

Fat loss (fasted, morning)

300–500 mcg SC daily on waking, then stay fasted 30–60 min. Insulin spikes wipe out the lipolytic effect - the fasted condition is not optional. Typical cycles 8–12 weeks.

Cartilage / joint use

250–500 mcg SC daily, often systemic. Site-adjacent injection is possible, but human protocols mostly rely on systemic activity. Animal data supports hyaluronic-acid synergy.

Stacking notes

AOD-9604 + Fragment 176-191 is redundant - both hit the same mechanism. AOD-9604 + GH-axis stack (CJC / Ipamorelin) is complementary: AOD provides the acute lipolysis wave, the GH stack provides the recovery / sleep axis.

Evidence snapshot

Tier: Human & Animal. Safety is Grade A - Phase 2 trials showed a clean profile. Efficacy is mixed: no significant edge over placebo for obesity, but that was a primary-endpoint trial without diet standardisation. Anecdotal body-comp data is real but tied to the fasted condition.

Human data

Stier 2013: Phase 2b for obesity, AOD-9604 vs placebo over 12 weeks - no significant weight-loss edge. Safety and tolerability data were clean, however. Development as a prescription obesity treatment was discontinued afterward.

Animal data

Robust lipolysis signal in rat and mouse models, particularly under fasted conditions. Kwon 2015: rabbit cartilage-repair model showed improvements with AOD-9604 + HA. Animal-to-human extrapolation remains open.

Safety considerations

One of the cleaner safety profiles in body-comp peptide space. No IGF-1 elevation means no GH-axis risks; no insulin effect means no glucose drift. Main concerns are efficacy risk (paying for a peptide that didn't beat placebo in Phase 2) and sourcing - AOD-9604 is non-standard synthesis and frequently mis-made in the grey market.

Common cautions

Efficacy is uncertain - failed to beat placebo in Phase 2 obesity trial
Fasted condition not optional - insulin spikes block lipolysis
Frequently mis-made in the grey market; recognising real AOD-9604 is hard without mass spectrometry
WADA S0 prohibited despite no proven human efficacy - status is non-approved rather than non-effective